文献速递临床试验与 GCP基础与转化研究

血管紧张素受体阻滞剂治疗COVID-19呼吸系统疾病的对照评估试验方案(CLARITY)

Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial.
PubMed 文献 · Trials · 2021-08-28

CLARITY是一项在印度和澳大利亚开展的多中心、适应性、两臂、比较有效性III期随机对照试验,旨在评估血管紧张素受体阻滞剂(ARB)能否降低高危COVID-19患者的疾病严重程度。主要终点为第14天7点序贯量表评分,研究采用频繁期中分析和预测概率进行样本量自适应调整。试验于2020年8月18日开始招募。

要点

  • ARB通过阻断AT1R可能减轻COVID-19呼吸道结局,且安全、低成本。
  • 主要终点为第14天7点序贯量表评分,范围从活动不受限到死亡。
  • 试验采用适应性设计,根据累积数据调整样本量并判断继续入组是否无效。

核心结论

  • CLARITY试验旨在验证ARB能否降低高危COVID-19患者的疾病严重程度。

研究设计与样本

  • 实用、适应性、两臂、多中心、比较有效性III期随机对照试验。
  • 在印度和澳大利亚招募,比较最大耐受日剂量ARB与标准治疗。
  • 印度采用盲法,澳大利亚因安慰剂供应中断采用开放标签。

关键数值与推荐

  • 主要终点为第14天7点序贯量表评分,从活动不受限(1分)到死亡(7分)。
  • 次要结局包括第28天7点量表评分及28天和90天死亡率。
  • 样本量通过频繁期中分析和预测概率进行自适应调整。

临床怎么用

  • 若试验证实有效,ARB可能成为高危COVID-19患者安全、低成本的呼吸结局改善方案。

局限性

  • 澳大利亚因安慰剂供应中断采用开放标签设计,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2 (ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key regulator of the renin-angiotensin system (RAS) and is responsible for degrading angiotensin II and thereby counteracting its pro-inflammatory, pro-fibrotic effects mediated through the angiotensin II type 1 receptor (AT1R). As AT1R is directly blocked by angiotensin receptor blockers (ARBs), these agents may offer a safe, low-cost solution for reducing COVID-19 respiratory outcomes. METHODS AND DISCUSSION: CLARITY is a pragmatic, adaptive, two-arm, multi-centre, comparative effectiveness phase III randomised controlled trial that examines whether ARBs reduce COVID-19 severity among high-risk patients. Recruiting in India and Australia, the trial will compare treatment with a maximum tolerated daily dose of an ARB to standard of care. Treatment allocation is blinded in India but open-label in Australia due to interruptions to placebo supply in the latter. The primary endpoint is a 7-point ordinal scale of clinical states, ranging from no limitation of activities (category 1) to death (category 7), assessed on day 14. Secondary outcomes include the 7-point scale assessed at day 28 and 28- and 90-day mortality. The design adapts the sample size based on accumulating data via frequent interim analyses and the use of predictive probability to determine whether the current sample size is sufficient or continuing accrual would be futile. The trial commenced recruitment on 18 August 2020. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04394117 . Registered on 19 May 2020. Clinical Trial Registry of India: CTRI/2020/07/026831).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Hockham C, Kotwal S, Wilcox A, et al. Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial. Trials. 2021. PMID: 34454580. doi:10.1186/s13063-021-05521-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。